Key Takeaways
- Revenue more than doubled, profit nearly quadrupled: Total income grew 116% YoY in Q2 FY26, while PAT rose nearly 4x, driven by operating leverage and a favorable product mix shift toward higher-value intermediates.
- A structural shift is underway, not just a bounce: The company is moving from a pure API player toward a diversified model spanning CDMO, backward-integrated KSMs, and industrial chemicals, with three innovator molecules in validation and an inorganic acquisition imminent.
- Margins are defended by chemistry, not pricing power: Management draws a hard floor at 25% EBITDA margin, citing proprietary methylation and Friedel-Crafts process technology, plus the flexibility to shift mix toward export markets that carry a 15–17% margin premium over domestic.
- The capacity story has a clear, funded path: A 700-ton expansion on adjoining land begins commissioning within Q3 FY26, funded entirely from IPO proceeds and internal accruals, with no new debt required.
- What to watch next quarter: Closure of the inorganic acquisition, progress on the three CDMO validations, and whether the confirmed ₹380 CR order book converts at the guided 25–27% blended EBITDA margin.
The Product Mix Shift: From API to a Broader Base
- Intermediate surge, API dip: In H1 FY26, intermediate contribution rose while API share fell, because product registrations that were pending last year came through, triggering overseas orders for N-1 KSM specifically for API production.
- Dexketoprofen dynamics: The hero product dexketoprofen is a forward integration of ketoprofen. Domestic customers buy the N-1 (backward integration of dexketoprofen), which is chemically the forward integration of ketoprofen. That supply is categorized as an intermediate, mechanically inflating the intermediate share even while API production continued.
- Export margin advantage: For domestic supply, raw material cost is kept at a maximum of 65% of selling price. For export, the cap is 50%, creating a 15–17% EBITDA gap that reflects the additional regulatory audit costs export markets require. Direct export is reported at 5%, but actual export including merchant exports through Indian agents will close the year at approximately 30%.
- Pricing pressure absorbed: API and intermediate prices fell 10–15% versus last year because Chinese manufacturers liquidated spare quantity under US tariff pressure. Management states the market has now stabilized and expects no further price pressure on confirmed contracts over the next year, since Anlon's products face hardly any domestic competition.
Punit Kumar Rasadia: "When we are supplying any product to any domestic customer, we are considering in mind that our raw material cost should not be more than 65% of our selling price. When we are going for the export, at that time we are keeping our raw material cost maximum 50%."
Capacity Expansion: The 700-Ton Build and the Logic Behind It
- Timeline and location: Construction and commissioning will start within Q3 FY26 (December 2025), with completion expected in 16–18 months. The expansion sits on adjoining land the company already owns, plus one additional land parcel, so it is not a fully new greenfield site requiring all-new statutory approvals, though environmental clearance will still be needed.
- Why not triple revenue: The revenue guidance of ₹360–400 CR at 1,100 tons total capacity is roughly double current levels, not triple, because the expansion takes 16–18 months and only six to seven months of revenue will be realized in the first year. Additionally, backward-integrated KSM manufactured at the new site will carry a lower selling price than API.
- Capacity utilization strategy: The existing Rajkot site is registered in all regulatory markets. To increase API capacity there, some intermediate steps (N-3, N-4) will be pulled out to the new facility. Both capacities will not produce APIs simultaneously, so revenue contribution from the new facility will be lower than the API price.
- Funding: ₹32 crore is planned for the expansion this year, sourced from ₹31 crore of IPO proceeds reserved for capex. No debt or bank loan is needed for this specific capex. If the inorganic acquisition is included, total capex rises to ₹50–55 crore.
- Multipurpose, existing molecules only: The 700-ton expansion is a multipurpose plant dedicated to existing molecules, with confirmed orders already in hand to fill it.
Punit Kumar Rasadia: "If we will not supply to our customer, then maybe there is a possibility that they will start to identify the new supplier. So we don't want to lose the business opportunity."
CDMO Entry and the Innovator Pipeline
- Three molecules, two global innovators: Anlon is developing three NC molecules for two innovator companies, one in Israel and one in Europe. Pilot validation is ongoing and expected to complete within the current quarter, with commercialization scheduled for Q3 FY27. This marks the company's entry into the high-value global CDMO space.
- Validation status: Validation has already been completed; three months of stability data are pending from the customer. Launches are expected by the third quarter of next year.
- New API launches: Artemether and Lumefantrine have already started production, with some quantity supplied within the current month. A revenue boost from these products is expected in the last quarter of the current fiscal or the first quarter of FY26.
- Regulatory catalysts ahead: An EU DMF has been applied to EDQM with confirmation received, and the CEP has already been applied. Management expects EU compliance by the end of this year. For the US, Anlon supplies a product to Sanofi Germany, which will trigger a USFDA audit in June 2026. Anlon's DMF is ready, and Sanofi will absorb the audit cost burden.
Inorganic Acquisition: Diversification and De-risking
- Dual purpose: The company has identified facilities and is actively pursuing an inorganic acquisition. One motivation is to avoid losing business due to capacity constraints at the existing site. Simultaneously, the acquisition target includes space for manufacturing basic and industrial chemicals used in agro, paint, and other industries, which carry no regulatory restrictions and will de-risk the API and intermediate portfolio by adding a new segment.
- Timeline: Management stated the acquisition may be finalized within this month or by the middle of next month, though no binding commitment was given.
- Revenue contribution: Peak revenue from the acquired facility's currently planned products is estimated at ₹300 CR, with potential upside if new intermediates or backward-integrated high-value raw materials are added.
- Funding stance: Management declined to specify how much debt would be needed, stating they plan to use IPO proceeds and reserve surplus and are not planning any debt. The stated ambition is to keep the company debt-free, with a target of achieving this by the last quarter of the next calendar year (third quarter of the next financial year).
Punit Kumar Rasadia: "Basically, we want to keep the company down the line debt-free."
Competitive Moat: Chemistry, Customer Concentration, and China Plus One
- Proprietary chemistry as the margin floor: Anlon's strength lies in specific methylation and Friedel-Crafts chemistry. The profane series of painkillers is highly sensitive to methylation chemistry, where the company claims to have the best process versus China and to be much more competitive. Management is "damn sure" that technology and operational efficiency will keep EBITDA margin above 25%.
- No Chinese KSM dependency: No KSM is sourced directly from China; only solvents and reagents come through domestic importers. All molecules are developed from basic scratch to avoid price-war risk, and molecules are selected specifically to ensure no raw material is China-dependent, aligning with customer China Plus One policies.
- Customer concentration explained: The high share of top-five customers reflects the API business structure. Products like dexketoprofen have only one Indian manufacturer (Anlon) supplying the global innovator (Minarini, with approximately 60% global market share), so a single customer accounts for large volume. In the domestic market, Anlon supplies through dealer and distributor networks in North Mumbai and Chennai, which appear as single customers in the books but actually serve more than 125 customers across India.
- The FY24 revenue drop: In 2022, Anlon filed a DMF in Brazil. A new guideline required physical audits for API manufacturers. Customer EMS, Brazil's number-two pharma company, audited and raised observations in production and storage areas. Anlon had to take a mandatory four-month shutdown, which stopped sales and caused the FY24 decline. That issue is now resolved, with Anvisa approval received with zero observations.
Punit Kumar Rasadia: "We are selecting some molecules in which there should not be any Chinese dependency, along with there is a possibility to become the world's largest in specific molecule."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Greenfield expansion start | Construction and commissioning to begin | Within Q3 FY26 (December 2025) |
| Greenfield expansion completion | 700-ton multipurpose plant for existing molecules | 16–18 months from start |
| CDMO commercialization | Three molecules for two global innovators | Q3 FY27 |
| Inorganic acquisition closure | Facility identified; may finalize | Within this month or by mid of next month |
| EU compliance | EDQM confirmation received; CEP applied | By end of this year |
| USFDA audit trigger | Sanofi to trigger audit; DMF ready | June 2026 |
| Debt-free target | Company to be debt-free | Last quarter of next calendar year (Q3 next financial year) |
| FY27 revenue minimum | ₹360–400 CR, conditioned on inorganic acquisition closing | FY27 |
| FY27/FY28 revenue potential | ₹500–550 CR across all three facilities after commercialization | FY27/FY28 |
| Confirmed order book | ~₹380 CR, approximately 50% export | Next year |
| Blended EBITDA margin | 25–27% on an annual basis | Ongoing |
| Trade receivables cleanup | No dues older than 180 days in books | By end of this financial year |
| Artemether and Lumefantrine revenue contribution | Meaningful boost expected | Last quarter current fiscal or Q1 FY26 |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Total income | ₹52.32 cr, +116% YoY vs ₹24.21 cr in Q2 FY25 |
| EBITDA | ₹13.77 cr, +82% YoY vs ₹7.57 cr in Q2 FY25 |
| PAT | ₹9.32 cr, nearly 4x YoY vs ₹2.59 cr in Q2 FY25 |
| Total income (H1 FY26) | ₹85.53 cr, +38% YoY vs ₹62.11 cr in H1 FY25 |
| EBITDA (H1 FY26) | ₹20.01 cr, +38% YoY vs ₹14.55 cr in H1 FY25 |
| PAT (H1 FY26) | ₹12.86 cr, doubled YoY vs ₹6.36 cr in H1 FY25 |
| Capacity utilization | 84% at Rajkot facility |
| API share in revenue mix (H1 FY26) | ~70% APIs, ~27.2% intermediates |
| Top 5 product contribution (H1 FY26) | ~78% of revenue |
| Export share | ~5% direct exports; expected to close FY26 at ~30% export |
| FY27 export target | At least 60% of revenue |
| FY26 revenue target | ₹180–200 cr from existing facility |
| FY27 revenue expectation | ₹360–400 cr minimum, after inorganic acquisition |
| Order book for FY27 | ~₹380 cr confirmed orders, ~50% export |
| Blended EBITDA margin guidance | 25–27% on an annual basis |
| Debt | ₹4.5 cr term loan; debt-equity ratio ~0.6–0.63 |
| Trade receivables | ₹107 cr, of which ~₹20–30 cr over six months old |
| Greenfield expansion capex | ₹32 cr planned; IPO proceeds reserved ₹31 cr |
| Inorganic acquisition size | ₹50–55 cr |
| CDMO commercialization timeline | Q3 FY27 for three molecules with two innovator companies |